Bio News
Moderna raised $2.6 billion by expanding its convertible bond offering. The company will use the proceeds from the sale of convertible bonds maturing in 2032 to expand its cancer therapeutics business and repay debt. The financing came shortly after Moderna announced the successful Phase 3 cancer vaccine results, and the company added $45 billion to its market capitalization on the day the results were disclosed.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
